Lisdexamfetamine Dimesylate Capsule Shortage: Current Availability and Manufacturer Updates
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Lisdexamfetamine Dimesylate capsules are currently experiencing supply disruptions, with several manufacturers reporting limited availability or active ingredient shortages through early 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Lisdexamfetamine Dimesylate.
What's in Shortage
Drug Name: Lisdexamfetamine Dimesylate Capsule
Brand Name: LISDEXAMFETAMINE DIMESYLATE
Dosage Form: Capsule (10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg)
Therapeutic Category: Psychiatry
Current Status: Current Shortage
Initial Posting Date: 07/14/2023
Last Updated: 02/04/2026
Which Manufacturers Are Affected
Supply status varies significantly by manufacturer and dosage strength:
- Alvogen: All strengths (10 mg - 70 mg) are currently Available. (Contact: 844-842-8672 / CustomerService-US@alvogen.com)
- Amneal Pharmaceuticals: All presentations (20 mg - 70 mg) are Unavailable due to active ingredient shortages. (Contact: 866-525-7270)
- Elite Laboratories, Inc.: All strengths (10 mg - 70 mg) are under Limited Availability. (Contact: 888-852-6657)
- Sun Pharmaceutical Industries, Inc.: All strengths (10 mg - 70 mg) are under Limited Availability, with additional supply anticipated in Q1 2026. (Contact: 800-818-4555)
- SpecGx LLC: All strengths (10 mg - 70 mg) are under Limited Availability and are being placed on allocation to customers. (Contact: 800-325-8888)
- Teva Pharmaceuticals USA, Inc.: Status varies by strength. Some are available, while others are under limited availability with estimated recovery dates in February or March 2026. (Contact: 800-545-8800)
- Lannett Company, Inc.: Mixed status. Some strengths (50 mg, 60 mg) are available, while others (10 mg, 70 mg) are unavailable or limited. (Contact: 844-834-0530)
- Mylan Pharmaceuticals Inc. (Viatris): Mixed status. Strengths 10 mg, 30 mg, 50 mg, and 70 mg are available; 20 mg, 40 mg, and 60 mg are unavailable. (Contact: 800-796-9526)
Why There's a Shortage
Several manufacturers, including Amneal and Mylan, have cited a shortage of an active ingredient as the reason for supply disruptions. Other manufacturers have reported limited availability or customer allocation without specifying a primary cause. Recovery for several impacted lines is estimated for the first quarter of 2026.
What Patients Should Do
If you are affected by this shortage, please consider the following steps:
- Consult Your Healthcare Provider: Discuss your treatment plan and potential alternatives with your doctor. Do not make changes to your medication without medical supervision.
- Speak with Your Pharmacist: Pharmacists may have information on which specific strengths or manufacturers are currently in stock at their location.
- Contact Manufacturers: You may use the contact information provided above to inquire about the availability of specific National Drug Codes (NDCs).
Disclaimer: This information is for educational purposes only. Patients should always consult with their healthcare provider regarding medical decisions and treatment options.
Source
FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.